# PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights
Canonical URL: https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-reports-first-quarter-2026-financial-results-and-corporate-highlights
Ticker: PMVP
Company: PMV Pharmaceuticals
Source: PMV Pharmaceuticals
Published: 2026-05-12 12:00 EST
Original Source URL: https://ir.pmvpharma.com
## Summary

Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancer New England Journal of Medicine published first-in-human rezatapopt data showing selective reactivation of mutant p53 in advanced solid tumors Rezatapopt New

## Article Body
Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancer New England Journal of Medicine published first-in-human rezatapopt data showing selective reactivation of mutant p53 in advanced solid tumors Rezatapopt New
## Recent Company News
- 2026-05-12 12:00 EST — [PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights](https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-reports-first-quarter-2026-financial-results-and-corporate-highlights) — Source: PMV Pharmaceuticals
- 2026-04-22 12:00 EST — [PMV Pharmaceuticals Announces Board Chair Transition](https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-announces-board-chair-transition) — Source: PMV Pharmaceuticals
- 2026-03-06 13:00 EST — [PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights](https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-reports-full-year-2025-financial-results-and-corporate-highlights) — Source: PMV Pharmaceuticals
- 2026-02-26 13:00 EST — [New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors](https://biopharmsignal.com/news/PMVP/new-england-journal-of-medicine-publishes-first-in-human-rezatapopt-data-showing-selective-reactivation-of-mutant-p53-in-advanced-solid-tumors) — Source: PMV Pharmaceuticals
- 2025-11-12 13:01 EST — [PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights](https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-reports-third-quarter-2025-financial-results-and-corporate-highlights) — Source: PMV Pharmaceuticals
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)